PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

Post-LOE

promethazine hydrochloride and dextromethorphan hydrobromide

R-Pharm US

ANDAORALSYRUP

Approved

Jun 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (promethazine hydrochloride and dextromethorphan hydrobromide) by R-Pharm US is clinical pharmacology dextromethorphan: dextromethorphan is an antitussive agent and, unlike the isomeric levorphanol, it has no analgesic or addictive properties. First approved in 2012.

Drug data last refreshed 23h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Dextromethorphan: Dextromethorphan is an antitussive agent and, unlike the isomeric levorphanol, it has no analgesic or addictive properties. The drug acts centrally and elevates the threshold for coughing. It is about equal to codeine in depressing the cough reflex. In…

Indications

Worked on PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.